Ultragenyx Pharmaceutical (RARE) Capital Leases (2019)
Ultragenyx Pharmaceutical's (RARE) quarterly Capital Leases came in at $31.2 million in Q3 2019, down 5.34% on a QoQ basis from $33.0 million in Q2 2019.
Ultragenyx Pharmaceutical (RARE) Capital Leases (2019) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has 1 years of Capital Leases data on file, last reported at $31.2 million in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Ultragenyx Pharmaceutical | 2.72 Bn | 2.31 Bn | 106.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 31.21 Mn |
| Jun 30, 2019 | 32.97 Mn |
| Mar 31, 2019 | 22.98 Mn |